Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01298752 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.

NCT NCT01298752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01298752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
Lead sponsor
Bausch & Lomb Incorporated
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2011
Completion date
November 30, 2011
Enrollment
177 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cataract, inflammation, pain